Streetbeat News

Analyst Ratings

FSLR

Susquehanna analyst Biju Perincheril maintains a Positive rating on First Solar (NASDAQ:FSLR) but lowers the price target from $285 to $280.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 3:48 pm

BOOT

UBS analyst Jay Sole maintains a Neutral rating on Boot Barn Holdings (NYSE:BOOT) but raises the price target from $127 to $165.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 3:47 pm

ADC

UBS analyst Michael Goldsmith has maintained a Neutral rating on Agree Realty (NYSE:ADC) while raising the price target from $72 to $77.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 3:46 pm

BLDP

Susquehanna analyst Biju Perincheril maintains a Neutral rating on Ballard Power Systems (NASDAQ:BLDP) and lowers the price target from $2 to $1.5.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 3:46 pm

BE

Susquehanna analyst Biju Perincheril maintains a Positive rating on Bloom Energy but lowers the price target from $16 to $13.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 3:45 pm

ARRY

Susquehanna analyst Biju Perincheril maintains a Positive rating on Array Technologies but lowers the price target from $14 to $10.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 3:43 pm

JNJ

Wells Fargo analyst Larry Biegelsen maintains an Equal-Weight rating on Johnson & Johnson and raises the price target from $163 to $166.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 3:43 pm

GWW

W.W. Grainger's stock received an upgrade from Baird, moving from Neutral to Outperform, with a price target increase from $975 to $1,230, leading to a rise in its share price.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 3:42 pm

ENPH

Susquehanna analyst Biju Perincheril has downgraded Enphase Energy from Positive to Neutral and reduced the price target from $147 to $104.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 3:42 pm

SLRN

Wells Fargo analyst Derek Archila has maintained an Overweight rating on Acelyrin (NASDAQ:SLRN) and raised the price target from $13 to $15.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 3:42 pm